Navidea Biopharmaceuticals has reported a net loss attributable to common stockholders of $9.12m, or $0.09 per share, for the third quarter ended 30 September 2012 compared to a net income attributable to common stockholders of $19.81m, or ...
Tags: Navidea Biopharmaceuticals, common stockholders, radiopharmaceutical
Ventana Medical Systems has received FDA approval for the application of its INFORM HER2 Dual ISH DNA Probe cocktail assay (HER2 Dual ISH) on the BenchMark ULTRA automated slide staining platform. The BenchMark XT instrument, the HER2 ...
Saladax Biomedical has signed a distribution contract with INyDIA Labs for My5-FU, a test that measures levels of 5-fluorouracil (5-FU), in the blood of cancer patients, in Spain and Protugal. INyDIA will provide My5-FU test kits to ...
Tags: medical research, medical test, clinical research, company collaboration
Saladax Biomedical has signed a diagnostic agreement with Eilaf Pharma for My5-FU diagnostic test in Egypt and throughout the Middle East North African (MENA) region. The test will measure the levels of an anti-cancer drug, ...
Tags: My5-FU diagnostic test, medical research, medical test
Skuldtech and AB Science have discovered a new set of blood markers predictive of a higher survival rate in pancreatic cancer patients. The companies are also planning to use the new markers for future companion test commercialization ...
Tags: skuldtech, AB science, blood markers, pancreatic cancer patients
Orexo and ProStrakan Group have reconfigured the commercial rights to the product, Abstral, in various territories worldwide. Abstral is the novel, rapidly-disintegrating, sublingual (under the tongue) formulation of fentanyl, and an ...
Immunovaccine has reported a net loss of $1.7m for the third quarter ended 30 September 2012 compared to a net loss of $1.5m for the same quarter in 2011. According to the company the increased loss is due to the $155,000 increase in ...
Tags: Net Loss, therapeutic cancer vaccine, immune enhancement technology
BioDelivery Sciences International (BDSI) has announced the introduction of Breakyl (fentanyl buccal film) in the European Union (EU) by Meda, its commercial partner for the product in the region. The launch triggered a $2.5m final EU ...
Celgene International Sàrl Abraxane, an albumin-bound form of paclitaxel, has demonstrated statistically significant improvementin overall survival for advanced pancreatic cancer patients in Phase III study. The Metastatic ...
Cancer Treatment Centers of America(CTCA)at Western Regional Medical Center(WRMC)in Arizona,US,has purchased BSD Medical's BSD-2000 Hyperthermia system. CTCA,which is comprised of a network of hospitals including WRMC,provides effective ...
Tags: CTCA, BSD 2000 Hyperthermia system, cancer treatments, WRMC
University of Miami Hospital and Clinics (UMHC) has purchased BSD Medical's MicroThermX microwave ablation system. With the purchase, UMHC will provide access to use MicroThermX system to its Sylvester Comprehensive Cancer Center and the ...
Dune Medical Devices has obtained an approvable letter related to its premarket approval application (PMA) for the breast cancer detection system from the US Food and Drug Administration (FDA). The letter indicates that the system's PMA ...
XBiotech has received FDA fast track designation for its anti-cachexia drug Xilonix, a first-in-class True Human antibody. Xilonix blocks an inflammatory substance (IL-1a) produced by the body in response to tumor growth, which plays a ...
IMRIS has received the US patent to use its MR guided radiation therapy in pelvic, brain, and head and neck imaging. The FDA-approved MR guided radiation therapy includes the combination of radiation therapy and a moveable magnet system. ...
Tags: IMRIS, MR image, radiation therapy
The US Patent and Trademark Office (USPTO) has issued a key patent covering the use of Galena Biopharma's NeuVax for inducing immunity to breast cancer recurrence in patients having low-to-intermediate IHC levels of 1+ or 2+ and a FISH ...